ArticleEmerging infectious diseases2020
Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity.
Article in Emerging infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Seroprevalence of IgG antibodies against SARS-CoV-2 in India, March 2020 to August 2021: a systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Pooled it
- Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis.Arthritis research & therapy · 2020Trial
- Population-based cross-sectional seroprevalence study of SARS-CoV-2 infection in urban residential areas in Ghana.BMJ public health · 2025Article
- The omicron variant of SARS-CoV-2 drove broadly increased seroprevalence in a public university setting.PLOS global public health · 2025Article
- Serodynamics: A primer and synthetic review of methods for epidemiological inference using serological data.Epidemics · 2024Review
- A seroprevalence study of SARS-CoV-2 and seasonal coronaviruses after the first SARS-CoV-2 circulation in New Caledonia, Pacific region.IJID regions · 2024Article
- Quantitating SARS-CoV-2 Neutralizing Antibodies from Human Dried Blood Spots.bioRxiv : the preprint server for biology · 2024Article
- Exploring cell-free assays for COVID-19 serosurvey.Scientific reports · 2024Article
- Prevalence and correlates of SARS-CoV-2 seropositivity among people who inject drugs in Baltimore, Maryland.Drug and alcohol dependence reports · 2023Article
- serosim: An R package for simulating serological data arising from vaccination, epidemiological and antibody kinetics processes.PLoS computational biology · 2023Article
- Trend in seroprevalence of SARS-CoV-2 (IgG antibody) among tribal-dominated population: Findings from Jharkhand, India.The Indian journal of medical research · 2022Article
- Severe Acute Respiratory Syndrome Coronavirus-2 - A Surge of CoronaVirus Disease-2019: An Epidemiological Study in Coimbatore District.Journal of pharmacy & bioallied sciences · 2022Article
- Serology as a Tool to Assess Infectious Disease Landscapes and Guide Public Health Policy.Pathogens (Basel, Switzerland) · 2022Review
- Population-based repeat cross-sectional seroprevalence survey of SARS-CoV-2 IgG antibodies in Pimpri Chinchwad Municipal Corporation Area, Maharashtra, India.Journal of family medicine and primary care · 2022Article
- Article
- High seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers.BMC infectious diseases · 2022Article
- Seroprevalence, spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of Chile.BMC infectious diseases · 2022Article
- Seroprevalence of SARS-CoV-2 Neutralizing Antibodies among Blood Donors in Ho Chi Minh City, Vietnam, August-November 2020.The American journal of tropical medicine and hygiene · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serologic studies are crucial for clarifying dynamics of the coronavirus disease pandemic. Past work on serologic studies (e.g., during influenza pandemics) has made relevant contributions, but specific conditions of the current situation require adaptation. Although detection of antibodies to measure exposure, immunity, or both seems straightforward conceptually, numerous challenges exist in terms of sample collection, what the presence of antibodies actually means, and appropriate analysis and interpretation to account for test accuracy and sampling biases. Successful deployment of serologic studies depends on type and performance of serologic tests, population studied, use of adequate study designs, and appropriate analysis and interpretation of data. We highlight key questions that serologic studies can help answer at different times, review strengths and limitations of different assay types and study designs, and discuss methods for rapid sharing and analysis of serologic data to determine global transmission of severe acute respiratory syndrome coronavirus 2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.